New Study Compares Efficacy and Safety of Once-Daily versus Twice-Daily PREZISTA® Regimen in Treatment-Experienced Adult Patients with No PREZISTA Mutations(Feb 17, 2010)

San Francisco, CA (February 17, 2010) – In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm.

read more

http://digg.com/u1NdLb